Omnio AB is a biopharmaceutical company specialized in the development of new drug products based on the protein plasminogen’s immune regulatory effects.
Omnio focuses on developing a novel biological drug for chronic wound healing where initial investigator-led treatments of patients with chronic wounds have shown great potential.
